Market Closed -
Bombay S.E.
06:00:53 2024-05-13 EDT
|
5-day change
|
1st Jan Change
|
12.13
INR
|
0.00%
|
|
0.00%
|
+49.20%
|
Fiscal Period: March |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
22.14
|
22.14
|
22.14
|
22.14
|
38.46
|
19.96
|
Enterprise Value (EV)
1 |
68.15
|
-0.0535
|
5.566
|
8.713
|
28.44
|
10.29
|
P/E ratio
|
-28.6
x
|
-6.48
x
|
-8.51
x
|
-5.93
x
|
-18.5
x
|
-15.3
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
251,581,818
x
|
39,839,118
x
|
-
|
EV / Revenue
|
-
|
-
|
-
|
99,014,386
x
|
29,453,449
x
|
-
|
EV / EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / FCF
|
-207
x
|
0
x
|
-1.16
x
|
-4
x
|
-11.1
x
|
97.7
x
|
FCF Yield
|
-0.48%
|
50,422%
|
-86.2%
|
-25%
|
-9.05%
|
1.02%
|
Price to Book
|
0.64
x
|
0.71
x
|
0.77
x
|
0.89
x
|
2.03
x
|
1.13
x
|
Nbr of stocks (in thousands)
|
6,436
|
6,436
|
6,436
|
6,436
|
5,425
|
5,425
|
Reference price
2 |
3.440
|
3.440
|
3.440
|
3.440
|
7.090
|
3.680
|
Announcement Date
|
18-09-05
|
19-08-31
|
20-09-30
|
21-09-08
|
22-06-28
|
23-09-05
|
Fiscal Period: March |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
|
-
|
-
|
-
|
0.088
|
0.9655
|
-
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-0.969
|
-36.55
|
-2.195
|
-3.139
|
-2.075
|
-1.278
|
Operating Margin
|
-
|
-
|
-
|
-3,566.72%
|
-214.89%
|
-
|
Earnings before Tax (EBT)
1 |
-0.6417
|
-2.882
|
-2.195
|
-3.139
|
-2.075
|
-1.278
|
Net income
1 |
-0.6417
|
-2.882
|
-2.195
|
-3.139
|
-2.075
|
-1.285
|
Net margin
|
-
|
-
|
-
|
-3,566.72%
|
-214.89%
|
-
|
EPS
2 |
-0.1203
|
-0.5308
|
-0.4044
|
-0.5800
|
-0.3822
|
-0.2400
|
Free Cash Flow
1 |
-0.3292
|
-26.99
|
-4.797
|
-2.177
|
-2.572
|
0.1052
|
FCF margin
|
-
|
-
|
-
|
-2,474.36%
|
-266.42%
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
18-09-05
|
19-08-31
|
20-09-30
|
21-09-08
|
22-06-28
|
23-09-05
|
Fiscal Period: March |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
46
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
22.2
|
16.6
|
13.4
|
10
|
9.68
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-0.33
|
-27
|
-4.8
|
-2.18
|
-2.57
|
0.11
|
ROE (net income / shareholders' equity)
|
-2.17%
|
-10.3%
|
-8.68%
|
-13.9%
|
-10.4%
|
-7%
|
ROA (Net income/ Total Assets)
|
-0.79%
|
-42.9%
|
-5.01%
|
-8.49%
|
-6.32%
|
-4.27%
|
Assets
1 |
80.87
|
6.715
|
43.82
|
36.99
|
32.81
|
30.09
|
Book Value Per Share
2 |
5.390
|
4.860
|
4.460
|
3.880
|
3.500
|
3.260
|
Cash Flow per Share
2 |
0.0200
|
4.090
|
3.050
|
2.470
|
1.850
|
1.780
|
Capex
1 |
0.02
|
0.74
|
-
|
-
|
-
|
-
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
18-09-05
|
19-08-31
|
20-09-30
|
21-09-08
|
22-06-28
|
23-09-05
|
|
1st Jan change
|
Capi.
|
---|
| +49.20% | 790K | | +37.74% | 723B | | +34.41% | 595B | | -2.07% | 369B | | +20.25% | 332B | | +2.99% | 282B | | +17.11% | 244B | | +9.73% | 208B | | -4.25% | 205B | | +2.81% | 168B |
Other Pharmaceuticals
|